What is ENGAGe? Who is ENGAGe? And what do we do? ENGAGe Executive - - PowerPoint PPT Presentation
What is ENGAGe? Who is ENGAGe? And what do we do? ENGAGe Executive Committee 2016-2019 Murat Gultekin (Co-Chair, Clinicien) Esra Urkmez (Co-Chair, Patient Advocacy) Birthe Lemley (Denmark) Michaela Simona Ene (Romania) Elisabeth Avall Lundqvist
ENGAGe Executive Committee 2016-2019 Murat Gultekin (Co-Chair, Clinicien) Esra Urkmez (Co-Chair, Patient Advocacy) Birthe Lemley (Denmark) Michaela Simona Ene (Romania) Elisabeth Avall Lundqvist (Sweden) Rene Laky (Austria) Cristiana Sessa (Switzerland)
1
https://engage.esgo.org/discover/about-engage/
Fact Sheets for Patients, Patient recommendations, Guidelines:
Fact Sheets for Patients What is Cervical Cancer (English, Spanish) - updated 2017 What is Ovarian Cancer (English, Spanish, Swedish) - updated 2017 What is Uterine Cancer (English) - 2018 What is a Clinical Trial (English, Spanish, Swedish) -2018 Gynecological Cancers in Europe Facts Sheets -2018 What is Vulvar Cancer - to be done from a scratch ESGO Patient recommendations and Guidelines Patient friendly version of different materials developed by ESGO for professionals will be designed to assist patients and their families
2012-2017 Achievements We Run, We Spin Against Cancer, We organize yearly Patient Seminars
3
TITLE OF THE STUDY:
ENGAGe Patient Survey 2017 in Europe - What patients want to tell their doctors?
OBJECTIVE :
From the mouth of patients, tell their doctors and heath care providers: What is being done good by their Health Care Team, What is missing in patient care and what areas need improvements?
TIMING:
Data collection was in field during August and September of 2017.
LOCATION:
The survey was conducted and finalized across Czech Republic, Denmark, Germany, Great Britain, Greece, Hungary, Poland, Serbia, Spain and Turkey.
SAMPLE:
The target group was Gynecologic Cancer Patients from 10 European Countries. Total of 1436 surveys were collected thru ENGAGe network. Survey has been translated into countries’ mother languages
METHOD:
The survey was carried out as online web interviewing (CAWI) and as pdf in person format: it used a structured questionnaire (10 demographic + 25 question on awareness, prevention, diagnosis, treatment, clinical trial and conclusion) prepared by ENGAGe Team, reviewed by Executive Team, volunteer doctors and Non Profit Organization Members within ENGAGe network.
Priviledged Educational Partner Supporter
5
AND to the TEAM who made it happen:
Murat Gultekin – ENGAGe CO-Chair, Renata Brandtnerova - Executive Director, ESGO Office David Cibula, ESGO President ENGAGe Committee 2016-2019
Murat Gultekin (Co-Chair, Clinicien) Esra Urkmez (Co-Chair, Patient Advocate) Birthe Lemley (Denmark) Michaela Simona Ene (Romania) Elisabeth Avall Lundqvist (Sweden) Rene Laky (Austria) Cristiana Sessa (Switzerland)
ESGO Prag Team - especially Lucie Lamlova, Quintiles IMS Team – Martin Vadura, Jiří Krýza Elif Andac Jones, Research Consultant and Political Sociologist at Georgetown University Luzia Travado, IPOS Board of Directors William S. Breitbart, Chair -Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering
6 Country Doctor / Patient Organization Country Doctor / Patient Organization Czech Republic - 173 Poland - 110 David Cibula Doctor Kamil Zalewski Doctor & Blue Butterfly foundation Veronika Cibulova Volunteer Serbia - 152 Michael Halaska Doctor Vesna Bondzic Women's Center Milica, Kraljevo Public Health institute Daniel Driak Doctor Spain - 113 Denmark - 125 Lucas Minig Doctor Birhte Lemley KIU Cristina Zorrero Doctor Germany - 119 Turkey - 182 Jalid Sehouli Stiftung Eierstock Krebs Muzaffer Sanci Doctor Susanne Fechner Stiftung Eierstock Krebs Murat Alan Doctor Jacek Grabowski Doctor Sevil Benli Kanserle Dans Association Gulhan Inci Doctor Asli Ortakmac Kanser Savascilari Greece - 108 UK - 231 Maria Papageorgiu K.E.F.I. of Athens Christina Fotopoulou Doctor Hungary - 123 Jonathan Ledermann Doctor Ildiko Nagy-Toth Mallow Flower Foundation Ross Little Ovarian Cancer Action
AND to the Patient Organizations and our Volunteer Doctors who distributed the survey thru online and in pdf form:
7
173 125 119 231 108 123 110 152 113 182 0.0 100.0 200.0 300.0 Czech Republic (CZE) Denmark (DNK) Germany (DEU) Great Britain (GBR) Greece (GRC) Hungary (HUN) Poland (POL) Serbia (SCG) Spain (ESP) Turkey (TUR)
Number of respondents by country- 1436 total
8
6.4% 5.6% 12.9% 7.7% 16.6% 13.0% 18.7% 13.6% 21.0% 24.7% 26.2% 20.2% 28.8% 34.0% 33.6% 54.6% 21.8% 18.5% 0% 20% 40% 60% 80% 100% TOTAL (N=1436) Currently under treatment (N=535) I have finished treatment (N=739) I have relapsed (N=162) up to year 2000 2001 - 2005 2006 - 2010 2011 - 2013 2014 - 2015 2016 - 2017
Current health condition – SORTED BY YEAR OF DIAGNOSIS
9
39.3% 41.0% 45.6% 74.8% 76.2% 11.1% 31.8% 9.2% 75.2% 11.5% 26.3% 6.7% 6.5% 76.4% 15.5% 74.3% 65.4% 15.3% 28.3% 7.4% 70.4% 20.0% 13.3% 15.9% 12.9% 19.1% 33.6% 12.6% 7.4% 18.7% 20.0% 10.5% 7.1% 6.0% 15.2% 10.2% 7.3% 0% 20% 40% 60% 80% 100% TOTAL (N=1436) CZE (N=173) DNK (N=125) DEU (N=119) GBR (N=231) GRC (N=108) HUN (N=123) POL (N=110) SCG (N=152) ESP (N=113) TUR (N=182) Ovarian cancer Breast cancer Uterine cancer Cervical cancer Fallopian tube cancer Vulval cancer Vaginal cancer
What type of cancer do you have? SORTED BY COUNTRY
10
AWARENESS - Knowledge of screenings/methods
Have you heard of any of the following screenings or methods that might help prevent these gynaecological cancers? SORTED BY COUNTRY The most frequently mentioned graphed – multiple choice question
56.5% 41.2% 33.2% 30.7% 24.4% 44.5% 39.9% 24.3% 5.2% 32.4% 37.6% 62.4% 39.2% 16.8% 38.7% 37.8% 31.1% 40.3% 32.8% 63.2% 45.5% 33.8% 55.8% 13.9% 81.5% 48.1% 42.6% 24.1% 9.3% 82.1% 82.9% 69.9% 37.4% 2.4% 70.9% 35.5% 30.9% 26.4% 23.6% 48.0% 19.1% 16.4% 17.8% 46.1% 47.8% 20.4% 16.8% 43.4% 29.2% 55.5% 27.5% 33.5% 19.8% 33.0%
0.0% 20.0% 40.0% 60.0% 80.0% 100.0% PAP smear for Cervical Carcinoma HPV vaccine for Cervical Carcinoma HPV test for Cervical Carcinoma BRCA Tests for Ovarian Carcinoma none of above mentioned TOTAL (N=1436) CZE (N=173) DNK (N=125) DEU (N=119) GBR (N=231) GRC (N=108) HUN (N=123) POL (N=110) SCG (N=152) ESP (N=113) TUR (N=182)
11
PREVENTION – Which of the following screening tests do you regularly attend?
SORTED BY COUNTRY
32.7% 17.3% 52.8% 38.7% 32.9% 58.3% 61.0% 16.4% 13.2% 15.9% 31.9% 27.6% 36.4% 7.2% 33.6% 8.2% 10.2% 44.5% 63.2% 45.1% 31.3% 24.9% 34.7% 12.8% 23.5% 36.8% 14.8% 22.8% 26.4% 15.1% 30.1% 21.4% 14.8% 11.6% 27.2% 22.1% 16.7% 15.4% 12.7% 8.6% 8.8% 15.4% 0% 20% 40% 60% 80% 100% TOTAL (N=1436) CZE (N=173) DNK (N=125) DEU (N=119) GBR (N=231) GRC (N=108) HUN (N=123) POL (N=110) SCG (N=152) ESP (N=113) TUR (N=182) cervical and breast cancer never followed routine cervical nor breast cancer screenings breast cancer cervical cancer
12
SO US PATIENTS, WHAT DO WE WANT TO TELL OUR HEALTH CARE PROVIDERS?
for Ovarian Carcinoma - WE WANT TO KNOW, WE NEED TO BE EDUCATED
finances to get them done, or we did not find them relevant to us. AGAIN, WE NEED TO BE EDUCATED, and WE NEED ACCESS TO THEM. We need to find a way on how we can improve the prevention in these countries, together. Don’t forget, numbers and studies are meaningless unless we do something with them
13
14
How would you describe your first conversation with your doctor/ nurse/ health care team? SORTED BY COUNTRY
44.7% 65.9% 35.2% 49.6% 37.7% 50.0% 43.9% 32.7% 36.2% 50.4% 45.1% 29.7% 19.7% 26.4% 39.5% 31.2% 23.1% 34.1% 30.9% 38.2% 28.3% 26.9% 16.6% 9.8% 34.4% 17.3% 22.2% 14.6% 20.0% 11.8% 10.6% 22.0% 9.1% 7.6% 13.9% 7.3% 16.4% 13.8% 10.6% 6.0% 0% 20% 40% 60% 80% 100% TOTAL (N=1436) CZE (N=173) DNK (N=125) DEU (N=119) GBR (N=231) GRC (N=108) HUN (N=123) POL (N=110) SCG (N=152) ESP (N=113) TUR (N=182) very good and clear - described everything about my disease and treatment good but I was in too big of much shock to process the information good, but not clear - the information was not very clear very distant, and not clear- the language they used was not clear to me
15
Did you received printed educational materials from your health care provider after your first conversation? SORTED BY COUNTRY
68.9% 64.2% 37.6% 72.3% 47.2% 95.4% 86.2% 76.4% 83.6% 75.2% 72.5% 31.1% 35.8% 62.4% 27.7% 52.8% 4.6% 13.8% 23.6% 16.4% 24.8% 27.5% 0% 20% 40% 60% 80% 100% TOTAL (N=1436) CZE (N=173) DNK (N=125) DEU (N=119) GBR (N=231) GRC (N=108) HUN (N=123) POL (N=110) SCG (N=152) ESP (N=113) TUR (N=182) no yes
16
Did you think these educational materials were helpful? SORTED BY COUNTRY
91.3% 95.2% 92.3% 87.9% 90.2% 60.0% 100.0% 76.9% 96.0% 100.0% 90.0% 8.7% 7.7% 12.1% 9.8% 40.0% 23.1% 10.0% 0% 20% 40% 60% 80% 100% TOTAL (N=446) CZE (N=62) DNK (N=78) DEU (N=33) GBR (N=122) GRC (N=5) HUN (N=17) POL (N=26) SCG (N=25) ESP (N=28) TUR (N=50) yes no
17
SO US PATIENTS, WHAT DO WE WANT TO TELL OUR DOCTORS WHO DIAGNOSE US FOR TREATMENT?
visits and we were too shocked to understand what you were telling us WE WANT PRINTED MATERIALS TO TAKE HOME, SO WHEN WE GET OVER THE SHOCK WE CAN EDUCATE ORSELVES AND OUR CAREGIVERS AT HOME HOW: We need to find a way to work together to achieve this. Patient
brochures, and we will need sponsors to do so. AGAIN… Don’t forget, numbers and studies are meaningless unless we do something with them
18
Waiting Time - How long did you have to wait before treatment started?
19
20
Were you offered any complimentary help? If yes, which of followings:
SORTED BY COUNTRY
34.9% 21.9% 17.4% 13.2% 9.0% 16.2% 4.0% 7.5% 8.7% 1.7% 25.6% 35.2% 10.4% 24.0% 5.6% 64.7% 26.1% 37.0% 54.6% 40.3% 31.6% 44.6% 12.6% 1.7% 9.5% 33.3% 25.9% 22.2% 7.4% 7.4% 17.1% 30.9% 8.1% 15.4% 0.8% 41.8% 4.5% 23.6% 22.7% 9.1% 28.3% 15.1% 17.8% 10.5% 2.6% 50.4% 21.2% 16.8% 1.8% 1.8% 48.4% 6.6% 24.7% 3.3% 13.2%
0.0% 20.0% 40.0% 60.0% 80.0% psychological support information on existing patient organizations or support groups diet recommendation / dietitian help rehabilitation programme social support TOTAL (N=1436) CZE (N=173) DNK (N=125) DEU (N=119) GBR (N=231) GRC (N=108) HUN (N=123) POL (N=110) SCG (N=152) ESP (N=113) TUR (N=182)
21
Evaluations of Doctors and Nurses by Patients: How strongly do you agree or disagree with the following statements?
22